![Willy Wiyatno](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profiel
Dr. Wiyatno joined Hercules Technology Capital Group in April 2006 focusing on the life science practice.
Prior to joining Hercules, he was a research scientist at Applied Biosystems (ABI) for four years where he focused on the development of emerging technologies in the areas of sample preparation, detection and analysis of DNA and proteins.
Willy is a lecturer at Stanford University and is currently pursuing his Chartered Financial Analyst accreditation.
He is an active board member of Golden Gate Polymer Forum (GGPF), a local non-profit organization dedicated to the advancement of materials and devices.
Willy obtained his Master and doctorate degrees in Chemical Engineering at Stanford University in 1999 and 2002, respectively.
He completed his bachelor degree at University of Wisconsin – Madison in 1997 in the area of Chemical Engineering.
Eerdere bekende functies van Willy Wiyatno
| Bedrijven | Functie | Einde |
|---|---|---|
Hercules Capital
 Hercules Capital Investment ManagersFinance Hercules Capital invests in public and private companies located in the United States. The firm focuses on technology and life science sectors. It participates in early, later, buyout and growth stage capital requirements in the form of debt and equity with investment size ranging from USD 5 to 500 million. | Private Equity Analist | 30-06-2007 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
10
Eerstegraads connecties
1
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 1 |
|---|---|
Hercules Capital
Hercules Capital Investment ManagersFinance Hercules Capital invests in public and private companies located in the United States. The firm focuses on technology and life science sectors. It participates in early, later, buyout and growth stage capital requirements in the form of debt and equity with investment size ranging from USD 5 to 500 million. | Finance |
